Point72 Asset Management
CCCC icon

Point72 Asset Management’s C4 Therapeutics CCCC Stock Holding History

Point72 Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$445K Sell
169,096
-9,270,232
-98% -$21.8M ﹤0.01% 3166
2025
Q4 		$18M Buy
+9,439,328
New +$22.4M 0.02% 961
2025
Q2 		– Sell
-236,855
Closed -$379K – 2223
2025
Q1 		$379K Buy
236,855
+40,389
+21% +$120K ﹤0.01% 1699
2024
Q4 		$707K Sell
196,466
-1,005,382
-84% -$5M ﹤0.01% 1567
2024
Q3 		$6.85M Buy
1,201,848
+923,268
+331% +$5.56M 0.02% 782
2024
Q2 		$1.29M Sell
278,580
-627,892
-69% -$3.74M ﹤0.01% 1205
2024
Q1 		$7.41M Sell
906,472
-1,054,887
-54% -$8.18M 0.02% 836
2023
Q4 		$11.1M Buy
1,961,359
+1,945,338
+12,142% +$4.44M 0.03% 650
2023
Q3 		$29.8K Buy
16,021
+9,464
+144% +$28.9K ﹤0.01% 2231
2023
Q2 		$18K Sell
6,557
-17,176
-72% -$55.2K ﹤0.01% 1805
2023
Q1 		$74.5K Buy
+23,733
New +$140K ﹤0.01% 1693
2022
Q2 		– Sell
-503,888
Closed -$12.2M – 1421
2022
Q1 		$12.2M Buy
+503,888
New +$12.2M 0.05% 458
2021
Q4 		– Sell
-200,000
Closed -$8.94M – 1113
2021
Q3 		$8.94M Buy
200,000
+34,400
+21% +$1.47M 0.04% 519
2021
Q2 		$6.27M Buy
+165,600
New +$5.93M 0.03% 560

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management's CCCC Position: Q1 2026 in Review

Point72 Asset Management reduced its C4 Therapeutics (CCCC) stake by 98% in Q1 2026, selling an estimated $21.8M and leaving 169,096 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

Point72 Asset Management first reported a position in CCCC in Q2 2021 and has held it in 14 quarters since. The position peaked at $18M in Q4 2025. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Point72 Asset Management held 169,096 shares of C4 Therapeutics worth $445K as of Q1 2026.
  • Point72 Asset Management sold 9,270,232 C4 Therapeutics shares in Q1 2026, an estimated $21.8M.
  • C4 Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3166 holding.
  • Point72 Asset Management first reported a position in C4 Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • Point72 Asset Management's C4 Therapeutics position peaked at $18M in Q4 2025.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.